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ABSTRACT
Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of 
other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation.  
However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of 
therapeutic agents of any kind to PDAC in particular has been hindered by the extensive 
desmoplasia and resultant drug delivery challenges that accompanies these tumors. 
Small interfering RNA (siRNA) is a promising modality for anti-neoplastic therapy due 
to its precision and wide range of potential therapeutic targets.  Unfortunately, siRNA 
therapy is limited by low serum half-life, vulnerability to intracellular digestion, and 
transient therapeutic effect. We assessed the ability of a peptide based, oligonucleotide 
condensing, endosomolytic nanoparticle (NP) system to deliver siRNA to KRAS-driven 
cancers.  We show that this peptide-based NP is avidly taken up by cancer cells 
in vitro, can deliver KRAS-specific siRNA, inhibit KRAS expression, and reduce cell 
viability. We further demonstrate that this system can deliver siRNA to the tumor 
microenvironment, reduce KRAS expression, and inhibit pancreatic cancer growth in 
vivo.  In a spontaneous KPPC model of PDAC, this system effectively delivers siRNA 
to stroma-rich tumors.  This model has the potential for translational relevance for 
patients with KRAS driven solid tumors.  
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INTRODUCTION
Despite being one of the most prevalent and well-
characterized proto-oncogene families, RAS proteins 
(HRAS, KRAS, NRAS) have largely eluded therapeutic 
intervention.  Collectively, these small GTPases represent 
the most frequently mutated oncogene family in human 
cancer, present in up to 30% of all cases [1].  In particular, 
the KRAS proto-oncogene accounts for approximately 
85% of all RAS mutations [2] and has been implicated 
in 95% of pancreas cancers [3] and 50% of colorectal 
cancers [4].  RAS encodes a 21-kD protein that cycles 
between an inactive, GDP-bound state, and an active, 
GTP-bound state.  GTPase activating proteins (GAPs) are 
responsible for inactivating KRAS by hydrolyzing GTP, 
but oncogenic mutations of KRAS, most commonly at 
codon G12, confer resistance to inactivation by GAPs 
[5].  This leads to constitutive activation of KRAS and 
upregulation of downstream signaling cascades that 
promote many of the hallmarks of cancer, including 
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sustained proliferation [6], metabolic reprogramming 
[7], resistance to apoptosis [8], immunological escape 
[9–11], cell migration [12], and metastasis [13, 14]. 
Mutant KRAS is well established as a true oncogenic 
driver – it is sufficient for neoplastic transformation 
in vitro [15], induces spontaneous tumor formation 
in genetically-engineered mouse models [16], and its 
expression is strictly required, even in advanced tumors 
[17].  Collectively, these features make KRAS one of the 
most attractive targets in cancer biology.
Indeed, in the 35 years since its discovery 
[18], KRAS has been the target of many attempts at 
pharmaceutical inhibition, including direct inhibition, 
interference with post-translational modification, 
disruption of membrane association, and interaction 
with downstream effectors [19]. However, no effective 
therapies targeting KRAS have entered the clinic, leading 
many to regard RAS oncoproteins as ‘undruggable’ [20]. 
Small-interfering RNA (siRNA) harbors tremendous 
therapeutic potential because it offers highly-specific, 
reversible control of gene expression [21].  A unique 
feature of siRNA therapy is the breadth of potential 
targets; essentially, any gene that is transcribed is a 
potential target.  However, utilization of siRNA in vivo 
has been challenging due to a short circulating half-life, 
limited cellular uptake, and cellular confinement within 
endosomes [22, 23]. Prior studies looking at nanoparticles 
(NPs) to target KRAS and its associated pathway 
via siRNA have utilized various NP compositions, 
but unfortunately none of these have yet to make it to 
the clinic  [24, 25]. Prior polymer and lipid based NP 
constructs are prone to cause generation of reactive 
oxygen species and calcium leakage, leading to off target 
effects, which is one potential advantage of our peptide 
based endosomolytic, oligonucleotide condensing NP 
[26–28]. In addition, the size of our NP (~55nm) and 
positive charge, unlike many prior NP formulations of 
various sizes and neutral or negative charge, enable us to 
target negatively charged tumor cells at the site of leaky 
tumor associated vasculature  [29–32].
Prior work from our group has demonstrated that 
our peptide based p5RHH NP efficiently combines with 
siRNA, is taken up into tumor cells via micropinocytosis, 
and encapsulated in endosomes, whereby upon 
acidification of endosomes the NP is able to lyse the 
endosome membrane and deliver siRNA into the 
cytoplasm of the cell (peptide based, endosomolytic, 
oligonucleotide condensing nanoparticle)  [26–28]. 
We hypothesized that this NP could deliver gene-level 
precision therapy to KRAS-driven tumors (Supplementary 
Figure 1). Herein, we employed this peptide-based 
nanocarrier, “p5RHH”, for the delivery of siRNA against 
KRAS, and assessed its propensity to: undergo cellular 
uptake, transmit siRNA, regulate gene expression, effect 
cellular viability, and alter tumor growth for KRAS-driven 
tumors.
RESULTS
Assessment of nanoparticle uptake in vitro
While this p5RHH oligonucleotide condensing, 
endosomolytic NP system has previously been used in 
vivo to successfully silence canonical NF-kB signaling 
in macrophages in models of rheumatoid arthritis and 
osteoarthritis [27, 28], we first wanted to assess the ability 
of this system to deliver siRNA into the cytoplasm of 
cancer cells in vitro. 
Fluorescent NP were administered to pancreatic 
and colorectal cancer cells in vitro, and fluorescent 
and confocal microscopy were used to assess uptake. 
Using confocal microscopy, fluorescent cytoplasmic 
signal appeared to develop beginning 4 hours after 
administration of fluorescent NP.  By 12 hours, the vast 
majority of cells appeared to contain fluorescent signal 
(Figure 1A). This strong signal continued at 24 hours time. 
Three-dimensional reconstruction images confirmed that 
fluorescent signal was present within the boundaries of the 
cell membrane, but was clearly distinct from lysosomes 
(Figure 1B).  
Administration of fluorescent NP to cancer cells 
in vitro demonstrated a consistently high degree of 
uptake across 7 cell lines, as seen via flow cytometry 
(Table 1).  The average percentage of cancer cells in a 
given line positive for fluorescent signal was 94.3%.  A 
representative flow cytometry plot demonstrates >99.9% 
positivity for murine pancreatic cancer (Figure 1C).  
Assessment of KRAS pathway silencing in vitro
After observing that every human and murine 
cancer cell line we tested took up fluorescent siRNA NP 
unequivocally and consistently, we next wanted to assess 
the efficacy of a silencing siRNA NP.  Two separate KRAS 
driven murine tumor cell lines (KPC-1 and CT26) were 
treated with KRAS-siRNA NP in vitro for 24 hours.  RNA 
was isolated from each group (3 replicates each) and RT-
PCR was performed. At 24 hours, we observed a highly 
significant decrease in KRAS expression in those groups 
treated with KRAS-siRNA NP versus control cells or 
scramble (SC) siRNA NP treated cells (both p < 0.0001), 
with a reduction in KRAS RNA expression from 55–70% 
(Figure 2A). Western blotting demonstrated a qualitative 
reduction in the expression of KRAS and downstream pERK 
after KRAS-siRNA NP treatment for 24 hours (Figure 2B). 
This reduction of KRAS protein expression persisted 48 
hours after administration (Supplementary Figure 2). 
Cell killing mechanism of KRAS silencing  
in vitro
After observing that treatment with KRAS-siRNA 
NP in vitro reduced KRAS expression, we aimed to 
determine if KRAS knockdown in these cells could 
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demonstrate any reduction in cell viability.  KPC-1 and 
CT26 KRAS mutant cell lines were either left unexposed, 
or exposed to KRAS-siRNA NP or SC-siRNA NP for 
48 hours. Cell death occurred in 53-55% of cells (both 
p<0.001) after treatment with KRAS-siRNA NP (Figure 
3A). On multiple comparison analysis, KRAS-siRNA 
NP treatment resulted in a significant reduction in 
viability compared to both control (both p<0.001) and 
SC-siRNA NP treated cells (both p<0.001), while there 
was no significant difference in viability between control 
cells and SC-siRNA NP treated cells. In addition, at the 
same exposure time point, cleaved caspase 3, a marker 
of cellular apoptosis, was found to be upregulated in the 
KRAS-siRNA NP treated cells (Figure 3B).
Assessment of nanoparticle uptake in vivo
We next wanted to assess the in vivo distribution 
of intravenously-injected NPs to determine whether our 
formulation could penetrate the tumor microenvironment. 
We inoculated mice with the KPC-1 murine PDAC cell 
line to form subcutaneous syngeneic tumors, and injected 
Figure 1: Intracytoplasmic delivery of siRNA by peptide nanoparticles in pancreatic and colorectal cancer is spatially 
separate from lysosomes and highly efficient.  (A) Confocal microscopy demonstrates diffuse cell uptake of fluorescent tagged 
siRNA bearing NPs (pink) at 12 hours in CT26 cancer cells (cell wall cyan). (B) Confocal microscopy focusing on a single KPC-1 cancer 
cell (cell wall cyan) demonstrates accumulation of fluorescent signal (pink) in the cytoplasmic compartment, distinct from lysosomes 
(yellow), after administration of fluorescent siRNA-bearing peptide NPs. (C) Representative flow cytometry plot showing penetration of 
siRNA into the cytoplasm of KPC-1 pancreatic cancer.
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Table 1: Nanoparticle uptake across multiple human and mouse pancreatic and colorectal cancers
Cell line Cancer species KRAS status Mutation Mutant alleles % NP uptake
Pancreatic Ductal Adenocarcinoma
BxPC-3 Human WT - - 96.7
Capan-1 Human MT G12V 2 92.3
KCKO Mouse MT G12D 1 83.5
KPC-1 Mouse MT G12A 1 99.6
Colorectal Adenocarcinoma
CT26 Mouse MT G12D 2 99.9
MC38 Mouse WT - - 93.8
WUC 322 Human MT G12D 1 94.0
NP = nanoparticle, WT = wild type, MT = mutant type.
Figure 2: KRAS expression is reduced significantly in KPC-1 pancreatic cancer cells and CT26 colorectal cancer cells. 
(A) RT-PCR demonstrates decreased KRAS RNA expression in pancreatic (left side graph) and colorectal (right side graph) cancer cells 
treated with KRAS-siRNA NPs (KRAS NP), as compared to untreated cells (Control) or cells treated with scramble siRNA NP (SC NP). 
(B)  CT26 colorectal cancer demonstrated decreased KRAS and phospho-ERK (pERK) expression after 24 hour treatment with KRAS NP 
treatment. ****=p < 0.0001, **=p < 0.01, 95% confidence intervals shown.
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(intravenous) these tumor-bearing mice with fluorescent 
siRNA-NP at specific tumor sizes, ranging from 2 mm to 2 
cm.  We evaluated tumor and organ fluorescence using an 
IVIS machine at serial time points post-injection.  Results 
were consistent across all mice and tumor sizes: NP signal 
was evident in the tumor, liver, and kidneys. Signal was 
evident in the blood and all major organs within the first 
hour of injection.  By six hours, signal was lost in the 
blood pool, but persisted in the tumor, liver, and kidneys. 
At 24 hours, the tumor, liver, and kidneys retained signal 
while the blood, brain, lungs, heart, pancreas, and spleen 
were negative (Figure 4A).  
To further characterize the fluorescence imaging 
results from IVIS, we performed flow cytometry on single 
cell suspensions of tumors and tissues from tumor-bearing 
mice that received fluorescent NP injections. Twenty-four 
hours after administration of IV fluorescent NP, the liver, 
kidney, and spleen suspensions demonstrated fluorescence 
in an average of 15.1%, 15.4%, and 10.1% of cells, 
respectively, while the tumor demonstrated fluorescence 
in 70.1% of cells (Figure 4B).  Representative flow 
cytometry plots are shown in Supplementary Figure 3.       
Being convinced that our NP could deliver siRNA 
to the tumor microenvironment for tumors derived from 
cell lines, we sought to evaluate whether the system 
could be used to deliver NP to spontaneously arising 
tumors. For this we used mice with KRAS G12D and 
biallelic p53 mutations expressed in pancreatic tissue 
Figure 3: Treatment of pancreatic and colorectal cells with KRAS-siRNA NP leads to apoptosis mediated cell death. 
(A) KPC-1 pancreatic cancer cells (left) and CT26 colorectal cancer cells (right) demonstrate increased percent cell death after treatment 
with KRAS-siRNA NP. (B) CT26 colorectal cancer cells treated for 48 hours with KRAS-siRNA NP show upregulation of cleaved caspase 
3. ****=p < 0.0001, ***=p < 0.001, 95% confidence intervals shown.
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(KPPC mice), which leads to spontaneous PDAC tumor 
formation. KPPC mice were injected with fluorescent NP, 
and pancreata and the remaining organs were harvested at 
24 hours post-injection. Fluorescent signal was detected 
in the liver and kidneys of these animals, but not in the 
brain, heart, lungs, or spleen. (Figure 4C).  Assessment 
of the pancreas revealed strong fluorescent signal in the 
fluorescent siRNA-NP injected animal (nearly 5 orders of 
magnitude greater radiant efficiency as compared to liver 
and kidney IVIS signal); signal appeared most strong 
in areas of pancreatic mass, with sparing of uninvolved 
pancreatic tissue (Figure 4D).  Fluorescence microscopy 
of the tumor confirmed siRNA delivery into the tumor 
microenvironment (Figure 4D). KPPC tumors have been 
shown to mirror the dense stromal infiltrate characteristic 
of human PDAC (Supplementary Figure 4) [33].
Assessment of in vivo nanoparticle safety
To establish the safety of the NP platform, we 
assessed potential toxic effects of our NP treatment by 
conducting hematologic and biochemical studies on non-
treated, and matched mice receiving SC- or KRAS-siRNA 
NPs. We focused these studies on renal and liver function, 
along with standard markers of inflammation and blood 
oxygen carrying capacity (Supplementary Figure 5). 
Figure 4: In-vivo tumor delivery of our nanoparticle construct. (A) The kidney, liver, and tumor of B6 mice growing KPC-1 
tumors fluoresce after IV injection of fluorescent siRNA NP.  (B) By flow cytometry, >70% of cells in the tumor are positive for fluorescent 
signal, while uptake in the kidney, liver and spleen is consistently < 20% ***indicates  p < 0.001. (C) In KPPC mice (p48-CRE/Lox-stop-
Lox(LSL)-KrasG12D/p53flox/flox), which develop spontaneous pancreas cancers, fluorescent signal is again seen in the liver and kidney using 
IVIS, consistent with excretion. (D) Fluorescent signal localizes to spontaneous pancreatic cancers with relative sparing of uninvolved 
pancreas, with IVIS results shown (top) and fluorescent microscopy (bottom). Quantification of IVIS in A, C, and D expressed as radiant 
efficiency ([photons/sec/cm2/steradian]/[W/cm2]). Please note scales showing order(s) of magnitude greater signal in tumors. 
Oncotarget4767www.oncotarget.com
There was no difference among control, SC-siRNA NP, or 
KRAS-siRNA NP injected animals with respect to white 
blood cell count, hemoglobin, platelet count, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
creatinine, or sodium (Na). There was a statistically 
significant difference in blood urea nitrogen (BUN) 
concentration between control and KRAS-siRNA NP 
treated mice (29.5 vs, 22 mg/dl, p<0.05), however the 
clinical relevance of this difference is likely minimal, and 
if anything renal function appears to be enhanced in the 
KRAS-siRNA NP treated mice. Due to the use of CO2 
euthanasia, serum potassium could not accurately be 
measured. The effect of our NP formulation on cardiac 
function was not assessed, as our p5RHH based NP has 
previously been shown to have no adverse effects on 
murine cardiac function in a model of atherosclerosis 
[34]. Finally, in studies looking at our p5RHH based NP in 
murine arthritis and atherosclerosis, after serial IV dosing, 
there was no activation of the innate or adaptive immune 
responses: namely, 1) no IgG or IgM to the intact peptide-
siRNA NP or peptide itself; 2) no suppression of innate 
immune responsivity by splenocytes (anti-CD3–activated 
CD4+ T cells secreting normal levels of TNF-α, IFN-γ, IL-
6, and IL-10); 3) no change in splenocyte subpopulations 
(CD4+ and CD8+ T cells, CD19+B cells, NK1.1+ natural 
killer cells, and Foxp3+ T regulatory cells); and 4) no 
activation of complement (C3a, 5a) [27, 28, 35]. 
Assessment of KRAS pathway silencing in vivo
Having established that NP injection could reach 
the tumor microenvironment and appears to be safe under 
these conditions, we next sought to determine if delivery 
of a functionally-active siRNA could induce silencing of 
gene expression.  KPC-1 tumor-bearing mice injected 
with anti-KRAS siRNA NP showed decreased tumoral 
KRAS protein expression as compared to SC-siRNA NP 
treated mice (Figure 5A). In addition, we demonstrated 
a robust, statistically significant, pERK knockdown after 
anti-KRAS NP treatment (p<0.05, Figure 5B and 5C, and 
Supplementary Table 1). 
Physiologic effect of KRAS silencing in vivo
To test the ability of an anti-KRAS NP to inhibit 
tumor growth, we inoculated mice subcutaneously 
with KPC-1 pancreatic cancer cells (2x105 cells per 
tumor injection).  Seven days after inoculation, mice 
were randomized to receive either SC-siRNA NP or 
KRAS-siRNA NP via tail vein injection.  Five days 
after the initiation of treatment (2 treatments), there was 
a statistically significant difference in tumor volume 
between the two groups (tumor size assessed three times 
weekly by caliper assessment), which was maintained for 
the duration of the 3.5 week experiment (Figure 6A).  The 
experiment was concluded at a point when any mouse 
developed ulceration of a tumor.  Tumor volume at the 
conclusion of the experiment was suppressed in the KRAS 
siRNA NP group (p<0.01, Figure 6B).  Representative 
images of the tumors at necropsy are seen in Figure 6C.
DISCUSSION
Unfortunately, PDAC harbors a 5-year survival 
of only 8% [36]. Even with the most efficacious 
chemotherapy regimen, consisting of Fluorouracil, 
Leucovirin, Irinotecan, and Oxaliplatin  (FOLFIRINOX), 
less than a third of patients with metastatic PDAC 
experience an objective response at 2 years follow-up, 
and median survival remains less than 1 year [37]. This 
large gap in treatment has led to a vast amount of research 
striving to improve survival in these patients; however, 
only a handful of clinical trials have yielded positive 
results [38].  These trials have invariably utilized standard, 
non-specific, traditional cytotoxic chemotherapeutic 
formulations and though survival has improved, it has 
been only by a few months.   
Multiple studies have consistently demonstrated 
the critical role of KRAS in the overwhelming majority 
of pancreatic cancers and many colorectal cancers [17, 
39]. A wide range of approaches to inhibiting mutant 
RAS have been explored in the three decades following 
its discovery as an oncogene, including: direct inhibition, 
interference with membrane association, inhibition of 
downstream effectors, and the exploitation of synthetic 
lethal interactors [19].  Despite this, no RAS inhibitor has 
reached the clinical arena.  Direct targeting of the KRAS 
protein has been particularly challenging because the 
most common KRAS mutation consists of a single amino 
acid substitution, which has been inaccessible to stearic 
inhibitors thus far [40].  
RNAi may represent a strategy to target KRAS 
while avoiding the challenge of inhibiting the protein 
directly. siRNA therapy is highly specific at the cellular 
level, and thus has the potential to have a favorable 
side effect profile, especially compared to cytotoxic 
chemotherapy.  This specificity is supported by early 
clinical trials utilizing siRNA, in which it appears to be 
safe and well-tolerated [41, 42]. While highly specific 
at the cellular level, tissue-type specificity, such as to 
solid tumors, has been a major barrier to siRNA therapy. 
Additionally, the dense stroma known to accompany 
PDAC further complicates delivery and has hampered 
multiple previous therapeutic attempts [43]. 
Despite these significant hurdles, there has 
been some recent success in using nanoparticle based 
therapeutics coupled with RNA interference, such as a 
paper by Pei et. al., whereby they demonstrate sequential 
targeting of TGF-β followed by KRAS, which led to 
tumor uptake and decreased KRAS expression in murine 
models of PDAC [44]. Other groups have also had some 
early success targeting KRAS in PDAC and CRC tumor 
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models [44–49].  Delivery to stroma rich PDAC remains 
the greatest challenge, and exciting novel strategies such 
as using superparamagnetic nanoparticles coupled with 
siRNA have also effectively targeted PDAC cells [47]. 
Other studies have utilized multiple non-KRAS siRNA 
targets to lead to therapeutic efficacy, such as one recent 
paper by Taniuchi and colleagues, whereby nanoparticles 
coupled to siRNA against six targets decreased prevalence 
of metastasis in vivo using murine PDAC models [48]. 
In this study, we show that a serum-stable, cell-
penetrating, oligonucleotide-condensing, endosomolytic 
peptide-based NP system can deliver siRNA against 
KRAS to KRAS-driven cancers, reducing KRAS pathway 
expression, and slowing KRAS-driven pancreatic cancer 
growth in vivo. We demonstrate delivery of siRNA to 
the tumor microenvironment in the PDAC model KPPC, 
which recapitulates the dense stromal architecture of 
human PDAC and closely mimics the natural history of 
human pancreatic cancer [33, 50]. Our research team’s 
peptide-based p5RHH oligonucleotide-condensing NP has 
prior to this only been utilized in vivo for cardiovascular 
and arthritis applications [27, 28, 35]. 
Penetrating the stroma-dense tumor 
microenvironment has been an ongoing challenge in 
treating PDAC.  Our NP system exploits the enhanced 
permeability and retention (EPR) effect that is known 
to accompany tumor vasculature. Though targeting 
moieties specific for PDAC have been used with 
Figure 5: Tumors treated with KRAS siRNA NP demonstrate knockdown of the KRAS signaling pathway. (A) KPC-1 
tumors from mice treated with KRAS-siRNA NP exhibit diminished KRAS protein level by Western blot analysis compared to scramble 
siRNA NP treated animals. (B) Looking at KPC-1 tumors from 7 mice/ group, with 5 20x images/ HPF taken, there was significant 
knockdown of pERK demonstrated in KRAS-siRNA NP (KRAS NP) treated mice. (C) H&E (top), and pERK IHC (bottom) images from 
control, scramble siRNA NP (SC NP) and KRAS NP treated mice. *=p < 0.05, standard error of the mean (SEM) shown.
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some prior NP formulations, successful delivery from 
the vasculature into the tumor microenvironment still 
relies on NP influx from permeable tumor-associated 
vasculature [25]. Thus, NP size, charge, shape and 
geometry are crucial. Prior data looking at optimal 
sizing of NPs has established the “goldilocks” size of 
50 nm (versus 20 or 200) being ideal for both ideal 
tumor microenvironment uptake and slow clearance 
[31]. In addition, much debate has occurred with regard 
to ideal NP charge, with no clear consensus of negative, 
neutral or positive NPs being more ideal [32]. Our NP 
construct is sized optimally at 55 nm, consistent with 
prior literature showing an ideal size of ~50 nm, with 
sizing situated to permeate leaky vasculature, stay at 
the tumor microenvironment, but not readily penetrate 
normal vascular barriers  [26]. Our particle also exploits 
differences in cellular charge, that we feel is optimal 
for tumor drug delivery. While most mammalian 
cells maintain a charge-neutral or slight net positive 
charge via ion pumps, cancer cells typically harbor a 
net negative charge due to increased glycolysis and 
lactate secretion  [26, 30].  Our p5RHH peptide NP 
system utilizes a positive charge (+12 mV) to promote 
preferential attraction to cancer cells, which differs from 
the majority of NP formulations used in the past, which 
tend to harbor a negative or neutral charge  [26, 51].  
In addition to the noted potential advantages in drug 
delivery, prior polymer and lipid based NP constructs are 
prone to cause generation of reactive oxygen species and 
calcium leakage, leading to off target effects [26–28, 52]. 
Our peptide based construct is predominantly cleared 
renally and has been found to have minimal off target 
effects both based on our data and our group’s prior work 
[26, 27, 29, 34]. One issue with prior peptide NPs had 
been endosomal uptake and sequestration, but our melittin 
derived p5RHH NP construct is by design endosomolytic 
and rapidly delivers siRNA to the cytoplasm of the 
target cell (Figure 1) [26]. Finally, although there may 
be concern regarding off targeting effect of our siRNA 
targeting KRAS, we demonstrated no significant toxicity 
in our murine model, with our KRAS siRNA or scramble 
siRNA NP (Supplementary Figure 5). This speaks to the 
lack of off target delivery of our p5RHH oligonucleotide 
condensing, endosomolytic NP construct (Figure 4).
We do acknowledge that there is variability seen in 
degree of KRAS knockdown across treatment groups in our 
in vivo experiments (Figure 5). However, the overall trend 
is clear, that KRAS signaling is suppressed after treatment 
with our KRAS-siRNA NP. Multiple factors such as timing 
of the last treatment dose and the timing of tumor takedown 
influenced data variability in our in vivo experiments, and 
although we strived to keep these variables as consistent as 
Figure 6: Demonstration of KPC-1 pancreatic cancer growth suppression in-vivo. (A) Treatment of KPC-1 tumor bearing 
mice, starting one week post tumor engraftment, with KRAS siRNA NP leads to a reduction in tumor growth rate versus that seen with 
scramble siRNA NP (SC NP) treatment. (B) Tumor volume is reduced 4.6 fold in mice receiving KRAS siRNA NP compared to mice 
receiving SC NP at 24 days. (C) Side by side ex-vivo images of KRAS-siRNA NP treated and scramble siRNA NP treated tumors. ***=p < 
0.001, *=p < 0.05, 95% confidence intervals shown.
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possible across groups, small variations were inevitable. In 
addition, although the small size and the positive charge of 
our NP make it uniquely capable of targeting cancer cells 
both in vitro and in vivo, we are working on incorporating 
targeting moieties into this NP system to further enhance 
specificity to tumor cells.
In summary, we demonstrate proof-of-concept that a 
serum-stable, cell-penetrating, and endosomolytic peptide-
based NP system can deliver siRNA against KRAS both 
in vitro and in vivo, including in a spontaneously-arising 
KPPC PDAC mouse model. This led to reduced KRAS 
expression, resulting in apoptosis of KRAS driven tumors, 
and inhibition of KRAS-driven PDAC growth in vivo. 
These results are significant because they show that NP 
systems can be used to preferentially target tumor tissue 
and robustly deliver siRNA, enabling precise gene-level 
control within a stroma-dense tumor microenvironment. 
While our system has been effective in limiting RAS 
expression, this system could theoretically be used to 
target other drivers of tumor progression.  
MATERIALS AND METHODS
Cell lines and maintenance
All cell lines were incubated in 5% CO2/95% air at 
37°C.  KPC-1 murine PDAC cells, which were initially 
derived from KPPC mice (p48-CRE/Lox-stop-Lox(LSL)-
KrasG12D/p53flox/flox) spontaneous PDAC tumors, were a 
generous gift from the laboratory of Dr. David DeNardo 
[53]. MC38 colorectal cancer cells were a generous gift of 
Dr. David Linehan. WUC 322 is an in-house derived cell 
line from a mutant type KRAS metastatic colorectal cancer 
patient. Additional cells lines BxPC3, CT26,  KCKO, and 
Capan-1 were obtained from the American Type Culture 
Collection (ATCC).  KPC-1 cell line was cultured with 
DMEM:F12 50/50 mixture (Gibco) with 10% FBS, 2.5% 
HEPES buffer, and 1% antibiotic-antimycotic (Gibco). 
CT26 cell lines were cultured in RPMI with 10% FBS, 
2.5% HEPES buffer and 1% antibiotic-antimycotic. 
The remaining cell lines were cultured in DMEM with 
10% FBS, 2.5% HEPES buffer, and 1% antibiotic-
antimycotic.  KPC-1 line was maintained in culture on 
collagen-coated plastic, while all others were cultured 
without collagen.  Cell lines were tested to confirm the 
absence of Mycoplasma.  Cells for both in vitro and in 
vivo experiments were harvested using 0.05% trypsin at 
approximately 75-85% confluence.  
Nanoparticle preparation
The oligonucleotide-condensing peptide p5RHH 
[26] was synthesized by solid phase methods at GenScript 
(Piscataway, NJ, USA). For in vitro studies, NPs were 
generated by combining 10 mcL of 20 mcM siRNA 
with 1 mcL of 20 mM p5RHH in an RNAase-free 
microcentrifuge tube with 389 mcL of Optimem media 
(Life Technologies, Carlsbad, CA, USA) to produce 
a 400 mcL solution. The mixture was incubated for 40 
minutes at 37° C.  During incubation, standard culture 
media was removed and replaced with 900 mcL Optimem. 
After incubation, 100 mcL of solution was added to each 
experimental well of a 6-well plate.  This was scaled as 
appropriate for different sized wells. 
For in vivo studies, 10 µL (100 µM) siRNA was 
combined with 5 µL (20mM) p5RHH in 185 mcL 
Hank’s Buffered Salt Solution (HBSS) with calcium and 
magnesium (Life Technologies, Carlsbad, CA, USA). 
The mixture was incubated on ice for 6 minutes and 30 
seconds.  A 0.3 mL insulin syringe (Terumo) was used 
to administer 150 mcL of the NP solution via tail vein 
injection.  These in vitro and in vivo protocols and have 
been reported previously [29].
siRNA
Fluorescent tagged siRNA (Quasar705) were 
obtained from Sigma-Aldrich.  Control siRNA 
(proprietary sequence) was obtained from GE Dharmacon. 
Targeted siRNA sequences purported to silence KRAS 
were obtained from Sigma-Aldrich and GE Dharmacon. 
siRNA was resuspended according to manufacturer’s 
instructions and RNA concentration was quantified 
using a NanoDrop microvolume spectrophotometer. 
siRNA concentrations were normalized and stored per 
manufacturer instructions.  Among siRNA obtained 
from Sigma-Aldrich and GE Dharmacon, Sigma-Aldrich 
KRAS siRNA sequence GUGCAAUGAGGGACCAGUA 
(5’-3’) and its complementary antisense strand 
UACUGGUCCCUCAUUGCAC (5’-3’) were found to 
be the most efficacious in reducing murine KRAS mutant 
cancer cell viability (CellTiterGlo Assay) via traditional 
transfection methods and within our NP construct and 
was therefore selected for subsequent experiments 
(Supplementary Figure 6).    
Confocal microscopy
NP containing a Quasar705 fluorochrome tagged 
siRNA was used. Cells were observed by confocal 
fluorescent microscopy in vitro throughout treatment. 
Confocal microscopy was performed using a Zeiss LSM 
880 confocal microscope.  Cell membrane staining was 
performed using CellMaskTM Orange (Life Technologies, 
Carlsbad, CA, USA) per manufacturer instructions. 
Lysosomal staining was performed using LysoTrackerTM 
Green DND-26 (Life Technologies, Carlsbad, CA, USA) 
per manufacturer instructions.   
Cell viability assay
Cell viability assays were performed using the 
CellTiterGlo® luminescent viability assay, which 
quantifies the amount of ATP present at the time of cell 
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lysis.  Cells were seeded into a 96-well plate with 90 mcL 
of media, allowed to settle for 24 hours, and then received 
either no treatment (addition of 10 mcL media), treatment 
with scramble siRNA NP (SC-siRNA NP, 10 mcL), or 
treatment with KRAS-siRNA NP (10 mcL).  Treatment 
lasted 48 hours, at which point the CellTiterGlo® assay 
was employed to determine cell viability.  One hundred 
microliters of CellTiterGlo® solution was added to each 
well.  Plates were gently agitated on an orbital shaker 
for 10 minutes, and luminescence was detected using a 
Biotek® Synergy HT plate reader at 450 nm.  
Animals and in vivo models 
Male and female C57BL/6 and NOD-SCID 
(Prkdcscid) mice, age 8 to 12 weeks, were obtained from 
the Jackson Laboratory and cared for in a barrier facility 
under guidelines established by the American Association 
for Accreditation of Laboratory Animal Care as well 
as the U.S. Public Health Service policy on Human 
Care and Use of Laboratory Animals.  The Washington 
University School of Medicine Institutional Animal 
Studies Committee approved all pertinent studies. Prior 
to injection into mice, cells were washed with PBS, and 
resuspended in 50 mcL of a 50/50 mixture of PBS and 
Matrigel (Corning).  For KPC-1 subcutaneous cancer 
models, C57BL/6 mice were anesthetized with ketamine/
xylazine, and after loss of pain reflex, placed in the lateral 
position, shaved, and injected with 2 x 105 cells into the 
right flank using a 30 Ga syringe (Terumo). KPPC mice 
(p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox) used 
in these studies have been previously described  [54] and 
were backcrossed to C57BL/6 background and screened 
for C57BL/6 identity using congenic markers.
For NP pharmacokinetic studies, mice were 
inoculated with cells as above.  Once tumors reached 
at least 5 mm in greatest dimension, a single 150 mcL 
injection of Q705 fluorescent-siRNA NP was administered 
via tail vein injection.  Twenty-four hours after injection, 
mice were sacrificed, and organs were imaged ex vivo 
using a Xenogen In Vivo Imaging System (IVIS).
For the subcutaneous KPC-1 pancreatic cancer 
model, mice were randomly assigned to receive no 
treatment, injection with SC-siRNA NP, or injection with 
KRAS-siRNA NP.  Injections began day 7 after tumor 
inoculation, and were administered three times weekly 
for 8 total treatments. For KRAS protein knockdown 
experiments, injections occurred three times weekly for 
1 week, followed by the mice being euthanized 24 hours 
after the 3rd treatment dose. Tumor dimensions were 
measured to the hundredth of a millimeter three times 
weekly with calipers, and tumor volumes were calculated 
using the formula: volume = (L x W x W)/2, whereby L 
represents the greatest dimension of the tumor, and W 
is the measurement perpendicular to L [55].  Mice with 
spontaneous tumor regression were eliminated from 
analysis.  Spontaneous tumor regression was defined as 
any tumor that fulfilled both criteria: 1) negative growth 
rate on three consecutive measurements, and 2) regression 
to a volume fifty percent or less than its maximum volume. 
Twenty-four days after treatment initiation, due to the 
development of tumor ulceration in some mice, all mice 
were sacrificed.  Tumor tissue was either snap frozen for 
lysate preparation, frozen in optimal cutting temperature 
(OCT) media, or fixed in formalin.
Flow cytometry
For in vitro flow cytometry experiments, cells 
were seeded in 6-well plates at a density of 2x105 cells 
per well, and allowed to settle for 24 hours.  Fluorescent 
particle was then administered.  Twenty-four hours 
after administration, cells were washed with PBS, 
trypsinized, washed with PBS again, and subjected to 
flow cytometry.  
Flow Cytometry was conducted using an LSRII 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). 
Preparation of cells in culture for single cell suspension 
consisted of trypsinization followed by one wash with 
FBS, then two washes with FACS buffer (1L 1x DPBS 
with 25 mM HEPES buffer, 5 mM EDTA, and 1% FBS). 
Gating and analysis were performed using FlowJo. 
Quasar705 was detected in the AF700 channel.  For 
analysis, the cutoff for Quasar705 (AF700) positivity 
was chosen at the point where >99% of control cells were 
negative. Identical gates were then applied to all samples. 
Cells below the cutoff were deemed ‘NP negative’ while 
cells above the cutoff were considered ‘NP positive.’
Quantitative real-time PCR
RNA was isolated from cells by suspension in Trizol 
(Life Technologies, Carlsbad, CA, USA), 1 mL per well 
for 6-well plates, followed by a Qiagen RNeasy RNA 
isolation kit (Hilden, Germany). RNA was quantified 
using a Qubit fluorometer (Thermo-Fischer Scientific, 
Grand Island, NY, USA).  cDNA was produced from 200 
ng RNA using a high-capacity cDNA reverse transcription 
kit (Applied Biosystems, Foster City, CA, USA). Primers 
(KRAS, beta-2-microglobulin, beta-actin, 18s rRNA) 
were obtained from Integrated DNA Technologies 
(Coralville, IA, USA). Real-Time PCR was performed on 
an Applied Biosystems 7500 Fast Real-Time PCR System 
(ThermoFischer Scientific, Grand Island, NY, USA) 
with SYBR Green reagents. PCR was done with reverse-
transcribed RNA and 500 ng/µL sense and antisense 
primer in 20 µL reactions. 40 cycles were performed, with 
each cycle consisting of 15 seconds of denaturation at 95 
°C followed by 1 minute of annealing and extension at 60 
°C. Beta-2-microglobulin expression consistently had the 
lowest standard deviation among candidate housekeeping 
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genes (beta-actin, GAPdH, 18s rRNA) and was therefore 
selected as the reference gene.  
Immunoblotting
Protein lysates were prepared using a Santa Cruz 
RIPA buffer system (Dallas, TX, USA) and quantified 
using a BCA Protein Assay kit (Lambda Biotech, Inc. Cat 
# G1002).  Lysates (60 µg/lane) were loaded and separated 
on a 4–12% Bis-Tris gel using a Biorad Electrophoresis 
system (Hercules, CA, USA). Proteins were transferred 
onto a PVDF membrane by wet electrophoresis, blocked 
with 5% milk for 1 hour at 4 °C, and incubated with 
primary antibody [KRAS, 1:2,000, Abcam ab55391; 
Vinculin, 1:10,000, Abcam ab129002; Caspase 3, 1:3000, 
Cell Signaling 9662S; Cleaved Caspase 3, 1:1000, Cell 
Signaling 9661S; Phospho-p44/42 MAPK (pERK 1/2), 
1:1000, Cell Signaling 9101; p44/42 MAPK (ERK 
1/2), 1:1000, Cell Signaling 9102] overnight.  After 
washing with TBST, membranes were incubated with 
secondary antibody [Anti-mouse IgG-HRP conjugate, 
1:5,000 (KRAS), Abcam ab97023; Anti-rabbit IgG-HRP 
conjugate, 1:2,000 (Vinculin, Total Caspase 3, ERK1/2, 
phosphor ERK1/2) or 1:1,000 (Cleaved Caspase 3), 
Cell Signaling (7074S)] for 1 hour at 4 °C under mild 
agitation.  Membranes were washed with TBST and 
incubated for 1 minute with HRP substrate (SuperSignal 
West Dura Extended Duration Substrate, ThermoFisher). 
Radiographic film was exposed to the blot and then 
developed in an automated radiograph developer. Various 
time points were used for in vitro studies, but for all in 
vivo data discussed mice were injected 3 times, every 
other day, starting after tumors reached ~0.5 centimeters, 
and taken down 24 hours after the final dose.  
Immunohistochemistry
Formalin fixed samples were dehydrated in 
sequential ethanol and then embedded in paraffin. 
Paraffin blocks of the samples were sectioned at 5µm 
thickness and then mounted to the slides. Slides were 
de-paraffinized and rehydrated through 2 xylene 
bathes, and sequential ethanol washes. Endogenous 
peroxidase was blocked with 0.3% H2O2 in methanol 
and then antigen retrieval was performed with a heated 
citrate buffer solution. The primary antibodies against 
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(Cell signaling, #4370, at 1:400) were diluted in 3% 
BSA in TBST and incubated at 4 degree overnight. 
HRP conjugated secondary antibodies was then added, 
washed, and finally, DAB-substrate (brown) was added 
for 3 minutes. This was then washed off. Counter stain 
was performed with Mayer’s hematoxylin (Thermo 
Scientific, 008011) and cover slips were mounted 
with Cytoseal XYL (Thermo Scientific, 8312-4). Halo 
Image Software Analysis (PerkinElmer) was utilized to 
quantify IHC signal from five 20x high powered fields 
(HPFs) per slide. IHC images using  smooth muscle actin 
(SMA) and sirius red were kindly obtained from the 
lab of Dr. David DeNardo. [33] For in vivo mechanistic 
studies utilizing immunohistochemistry, a cohort of 7 
mice per group (untreated, SC-siRNA treated, or KRAS-
siRNA treated) received 8 equally-spaced injections over 
2.5 weeks, followed by mouse takedown 1 week after 
stopping treatments.
Statistical analysis
For animal experiments, 10 mice were assigned 
per treatment group. Tumor volumes for each group were 
compared using the Student t test (equal variances) or 
Welch’s t test (unequal variances) for comparisons of two 
groups.  For comparisons among multiple groups, ANOVA 
was used. If the ANOVA was statistically significant, 
Tukey’s multiple comparison was used to compare 
between individual groups. All data were normal according 
to D’Agostino-Pearson omnibus and Kolmogorov-
Smirnov testing.  A p value ≤0.05 was deemed statistically 
significant. All statistical tests were two-sided and were 
performed using GraphPad Prism 7.01.
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